Cat. No. 3162
Biological ActivityUrotensin-II (UT) receptor pure antagonist (pEC50 = 7.24). Displays no agonist activity unlike other U-II/URP analogs. Inhibits the action of U-II in the rat aorta ring assay.
(Modifications: X = Orn, Disulfide bridge between 2 - 7)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Diallo et al (2008) [Orn5]URP acts as a pure antagonist of urotensinergic receptors in rat cortical astrocytes. Peptides 29 813. PMID: 18082287.
Chatenet et al (2004) Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides 25 1819. PMID: 15476952.
If you know of a relevant reference for [Orn5]-URP please let us know.
Citations are publications that use Tocris products. Selected citations for [Orn5]-URP include:
Lee et al (2014) Urotensin II induces interleukin 8 expression in human umbilical vein endothelial cells. PLoS One 9 e90278. PMID: 24587311.
Do you know of a great paper that uses [Orn5]-URP from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: [Orn5]-URP, supplier, Urotensin-II, UT, receptor, antagonists, Receptors, Tocris Bioscience, Urotensin-II Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Negative control for ELA-32 (Cat.No.6291).ELA-32 (human)
Potent, high affinity apelin receptor agonist; stimulates angiogenesisParathyroid hormone (1-34) (bovine)
Parathyroid hormone (PTH) receptor agonist.Parathyroid hormone (1-34) (rat)
Parathyroid hormone (PTH) receptor agonistPeptide YY (3-36) human
NPY Y2 receptor agonistELA-14 negative control
Negative control for ELA-14 (Cat.No.6293).ELA-14 (human)
Potent apelin (APJ) receptor agonistRetrobradykinin
Reverse analog of BradykininTASP 0390325
Potent and selective V1B receptor antagonist; orally bioavailable
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.